Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PD-1
Biotech
AnaptysBio's PD-1 drug reduces rheumatoid arthritis in phase 2
All three doses hit the trial’s primary endpoint that showed a statistically significant change from baseline in disease activity after 12 weeks.
James Waldron
Feb 12, 2025 9:57am
Will Novartis catch the PD-1 bispecific wave? CEO weighs in
Jan 31, 2025 3:30am
Pfizer's PD-1 prospect hits goal in phase 3 bladder cancer study
Jan 10, 2025 6:45am
Ottimo raises $140M to ready PD1/VEGFR2 antibody for clinic
Dec 19, 2024 6:58am
HanxBio plans Hong Kong IPO to fund phase 2 solid tumor trial
Nov 25, 2024 9:20am
Engineered yeast delivers PD-1 inhibitors, shrinks mice tumors
Nov 22, 2024 3:12pm
